'Cell knife' for cancer: the clinician's perspective.

Clicks: 83
ID: 281549
2025
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #101 of 111 articles by views in Frontiers in immunology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Boron Neutron Capture Therapy (BNCT), often referred to as the 'cell knife,' represents a binary, tumor-selective therapeutic modality that minimizes damage to surrounding healthy tissues. This review provides a comprehensive clinical perspective on BNCT, addressing the radiobiological mechanisms and summarizing related clinical trials, with a particular emphasis on glioma and head and neck cancers. Furthermore, the paper touches upon the synergistic potential of BNCT when integrated with other treatment modalities, such as proton and carbon ion radiotherapy, alternative neutron capture therapies, ultrasound, and immunotherapy. These combined approaches may offer promising avenues for future research, potentially enhancing the therapeutic index and expanding the applicability of BNCT in oncological practice.
Reference Key
zhou2025cell Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Zhou, Zihan; Chen, Yunhao; Wang, Yao; Hong, Yafang; Guan, Hongdan; Huang, Fenghao; Fu, Fenfang; Li, Xiaobo; Zheng, Rong; Xu, Benhua
Journal Frontiers in immunology
Year 2025
DOI
10.3389/fimmu.2025.1536355
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.